Sotorasib vs. Docetaxel for Previously Treated NSCLC With KRAS G12C Mutation: CodeBreaK 200 Phase III Study | VuMedi

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

10 seconds

Playback speed

ESMO 2022 Conference Coverage

Sotorasib vs. Docetaxel for Previously Treated NSCLC With KRAS G12C Mutation: CodeBreaK 200 Phase III Study

By ESMO 2022 Conference Coverage FEATURING Melissa Johnson

By ESMO 2022 Conference Coverage FEATURING Melissa Johnson

738 views

December 30, 2022

Comments 0

Login to view comments. Click here to Login